Dr. John Cush RheumNow
6 years 2 months ago
Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01]. IIM CV risk only present 1st 5 years https://t.co/EyD3GHv2YY
Dr. John Cush RheumNow
6 years 2 months ago
Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis. Dysphagia may be complicated by aspiration pneumonia https://t.co/wDg3tWaooP
Victoria Shanmugam VickiShanmugam
6 years 2 months ago
The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets
https://t.co/IWbiVw9PSP
Dr. John Cush RheumNow
6 years 2 months ago
NY Times Ranks COVID Rx Tracker: 1) Strong Evidence - Remdesivir, dexamethasone, Ventilation, Proning, anticoagulants; 2) Promising: convalescent plasma, Cytosorb, dialysis; 3) Mixed: IFN, Cytokine inhibitors, Stem Cells; 4) HCQ -not promising https://t.co/sbotsdYcg8
Dr. John Cush RheumNow
6 years 2 months ago
Ghent Univ experience and literature review shows that diffuse and localized scleroderma occurs in 2.4 to 7.4% often with Raynauds (6/8), scleroderma pattern on nailfold videocapillaroscopy and SSc-specific autoantibodies https://t.co/zDgXsuKD3p
Dr. John Cush RheumNow
6 years 2 months ago
Italian report of 2 cases (1 w/ stable RA;1 without prior arthritis) who developed polyarthritis after hospitalization for COVID pneumonia. Synovial Bx showed synovial proliferation - 1 w/ crystals and both w/ CD3+ and CD138+ cells https://t.co/ZRRrWIjZXg
Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial. The mechanistic effects of these agents, either presumed antiviral, anti-inflammatory and anti-thrombotic effects, may benefit mitigate the damage seen with COVID-19 infection.
This review will examine the potential benefits and existing evidence for treating suspected or proven COVID-19 infection with antimalarials,
Dr. John Cush RheumNow
6 years 3 months ago
JAMA Internal Medicine reports that the number of hydroxychloroquine prescriptions increased from 367,346 to 683,999 (86.2%) from February to March 2020, and chloroquine prescriptions increased 158.6%, rising from 2,346 to 6,066 prescriptions. https://t.co/3MKsu5mOpx
Dr. John Cush RheumNow
6 years 3 months ago
Rheumatology reports a UK study of Clinical Practice Research Datalink and 17 760 incident RA pts; 42% who recv steroids; The HTN rate was 64.1 per 1000 PY & GC use assoc w/ 17% increased risk HTN (hazard ratio 1.17), esp at doses > 7.5 mg/d https://t.co/31Q2xiwvMp
Dr. John Cush RheumNow
6 years 3 months ago
Canadian 1484 incident early #RA pts (enrolled 2007–2017). SC MTX monotherapy had fewer Rx changes(45% SC vs 79% PO)with longer treatment duration. Similarly taking biologics or triple therapy had a longer time without treatment change. https://t.co/babj1MvTNB
The Lancet Rheumatology TheLancetRheum
6 years 3 months ago
NEW #COVID19—"Symmetric peripheral polyarthritis developed during #SARSCoV2 infection"
Comment by Rosario Talarico and colleagues https://t.co/IqHp2GMLao #LancetRheumatology https://t.co/v3MBNDUnzG
The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.
Dr. John Cush RheumNow
6 years 3 months ago
FDA has approved guselkumab (Tremfya) for active psoriatic arthritis, making it the 1st IL-23 inhibitor approved for PsA. Approval is based on DISCOVER-1 & DISCOVER-2 RCTs. Dosing: 100 mg SC q8 wks after loading dose at 0, 4 wks. https://t.co/1nCWuC1zii
A one year head-to-head (H2H) trial has shown ixekizumab (IXE) to be superior to adalimumab (ADA) in psoriatic arthritis (PsA); for both skin and articular outcomes.
The SPIRIT H2H study was a 52-week trial of 566 biologic DMARD naive, PsA patients, randomized to received either IXE or ADA. The primary end point was at Wk 24, but the newly published data shows week 52 results for ACR50 and Psoriasis Area and Severity Index 100
